SEARCH

SEARCH BY CITATION

References

  • 1
    Allergen immunotherapy: specific vaccines for all_ergic diseases. WHO position paper. Bousquet J, Lockey RF, Mall_ing H-J, editors. Allergy 1998;53 Suppl 52:434.
  • 2
    Mall_ing H-J, Abreu-Nogueira L, Alvarez-Cuesta E, et al. EAACI/ESPACI position paper on local immunotherapy. Allergy 1998;53:933944.
  • 3
    Almangro E, Asensio O, Bartolomé M, et al. Estudio multicentrico de farmacovigilancia de inmunoterapia sublingual en pacientes alergicos. Allergol Immunopathol (Madr) 1995;23:153159.
  • 4
    André C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swall_ow immunotherapy in children and adults. Int Arch Allergy Immunol 2000;121:229234.
  • 5
    Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999;55:11101113.
  • 6
    Frew AJ, White PJ, Smith HE. Sublingual immunotherapy. J Allergy Clin Immunol 1999;104:267270.
  • 7
    Ragusa FV, Passalacqua G, Gambardella G, et al. Nonfatal systemic reactions due to subcutaneous immunotherapy: a 10-year experience. J Investig Allergol Clin Immunol 1997;7:151154.
  • 8
    Mistrello G, Brenna O, Roncarolo D, et al. Monomeric chemicall_y modified all_ergens: immunologic and physicochemical characterization. Allergy 1996;51:815.
  • 9
    Bagnasco M, Passalacqua G, Villa G, et al. Pharmacokinetics of an all_ergen and a monomeric all_ergoid for oromucosal immunotherapy in all_ergic volunteers. Clin Exp Allergy 2001;31:5460.
  • 10
    Lombardi C, Canonica GW, Passalacqua G. Sublingual IT in OAS. Allergy 2000;55:677678.DOI: 10.1034/j.1398-9995.2000.00687.x